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from receiving best practice treatment every year3. Our 
vision for Nano-X is to provide a cost-effective solution for 
radiotherapy treatment by moving much of the complexity 
from the hardware to the software. Our aim is to produce a 
commercially viable system within three years. 
Materials and Methods: The Nano-X collaboration has utilised 
patient rotation technology to significantly reduce the 
complexity, and thus cost, of radiotherapy. Patient rotation 
technology allows the patient to be mechanically moved 
during treatment, in contrast to a conventional device which 
moves the linac, typically weighing about 3T, around a fixed 
patient position. This allows the use of a static linac and thus 
also reduces the size and cost of the bunker. The Nano-X 
includes a 6MV linac with MLC, MV panel and a novel kV cone-
beam imaging system. The integrated imaging systems allow 
for real-time and adaptive image guided therapy which will 
alleviate the requirements of pre-treatment patient 
alignment reducing the on-site staffing burden. 
Results: The Nano-X prototype is currently under 
construction by LinaTech Medical Technologies Ltd and is due 
for completion and installation at Nelune Comprehensive 
Cancer Centre (NCCC) in 2015, with a planned commercial 
product available in 3 years. The initial estimated cost of a 
commercial Nano-X is around 10% of the cost of a 
conventional RT machine, with bunker costs reduced by up to 
67%2. 
Conclusions: With the low-cost and design that is specifically 
tailored towards LIMCs as well as rural and remote regions 
the Nano-X represents a solution to RT availability 
worldwide. The Nano-X prototype is currently under 
construction and will be installed at NCCC in 2015. 
Discussions are underway to determine the first LMIC 
treatment site. 
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Purpose/Objective: Alterations in metabolism seem to 
influence initiation of malignancy as well as recurrence. 
However the effect of diabetes, as one of the most common 
endocrine disorders, and metformin therapy on glioblastoma 
(GBM), remain understudied. Our aim is to examine the 
influence of diabetes and metformin on progression and 
survival in GBM patients.  
Materials and Methods: 270 patients with primary 
glioblastoma underwent radiation therapy between 2007 and 
2011 at the XXX. We assessed clinical records as well as 
pretherapeutic and follow up MR-imaging. 33 patients (12.2 
%) were identified with a pretherapeutic history of diabetes, 
treated with metformin in 14 cases (42.4 %). Survival and 
correlations were calculated using the t-test, log-rank 
analysis and univariate cox proportional hazards ratio. 
Results: Diabetes was associated with significant decreased 
overall survival rates (p = .047) in GBM patients in the 
prognostic favorable subgroup without corticosteroid 
therapy. Furthermore persistent mild - (p < .001) and 
persistent excessive hyperglycemia (p < .001) correlated with 
decreased survival. Interestingly, diabetic patients with 
metformin therapy showed a prolonged progression-free 
interval (p = .037). Recurrence patterns were not affected by 
diabetes or metformin therapy. 
Conclusions: We could show an adverse relationship between 
diabetes and survival in GBM patients. Furthermore our 
clinical findings suggest that metformin therapy prolongs the 
progression-free survival in GBM patients with diabetes. 
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Purpose/Objective: The prognosis in patients with high grade 
glioma remains poor, and the use of dose escalation beyond 
60 Gy using three-dimensional conformal radiotherapy (RT) or 
intensity-modulated radiotherapy (IMRT) has not lead to a 
survival benefit. Previous experimental and clinical studies 
indicated that hyperbaric oxygen (HBO) therapy could 
enhance an antitumor effect of RT. A few clinical studies 
indicated that HBO therapy immediately before conventional 
RT was safe and seemed to be effective in patients with high 
grade glioma. We conducted the combination therapy of 
chemoradiotherapy (CRT) using IMRT boosts in combination 
with HBO therapy. The purpose of this study was to evaluate 
the feasibility and efficacy of the combination therapy.  
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Materials and Methods: Between April 2008 and September 
2013, 33 patients with high grade glioma were treated with 
CRT using IMRT boosts in combination with HBO therapy. 
Twenty four (73%) patients have a tumor with WHO 
classification of Grade IV, and 9 (27%) patients have a Grade 
III. Before CRT, tumor resection was performed in 26 (79%) 
patients, and tumor biopsy was in 7 (21%) patients. The 
protocol of RT was as follows; first, three-dimensional 
conformal RT were delivered 40 Gy/20 fractions (fr)/daily 
2.0Gy to the GTV and surrounding edema plus 1.5 to 2.0cm as 
the clinical target volume extended (CTV-e). Continuously, 
the IMRT boosts using Cyberknife were delivered 28 Gy/8 
fr/daily 3.5 Gy to the GTV and 16 Gy/8 fr/daily 2.0 Gy to the 
surrounding edema defined as the clinical target volume 
annulus (CTV-a). HBO therapy was performed immediately 
before each IMRT boost session, and was a single treatment 
for 60 minutes in a monoplace HBO chamber pressured with 
100% oxygen to 2.0 atmospheres absolute. Temozolomide as 
a concurrent or adjuvant chemotherapy was administrated in 
29 (88%) patients. Feasibility and efficacy of this combined 
therapy were retrospectively analyzed.  
Results: Planned RT dose was completed in all patients, 
while HBO therapy was terminated in 2 (6%) patients due to 
aural pain of Grade 2 at first and second session. Radiation 
necrosis of the brain of Grade 2 occurred in 3 (9%) patients. 
Acute and late toxicities were mild, no Grade 3 or higher 
toxicity was observed in any of the patients. The median 
follow-up duration was 17 months. The median local 
progression-free survival time was 16 months. Median overall 
survival times were 23 months with Grade IV and 30 months 
with grade III, respectively. Eastern Cooperative Oncology 
Group (ECOG) performance status of 0-1 resulted in better 
overall survival rates (p<0.01). 
Conclusions: The combined therapy of CRT using IMRT boosts 
in combination with HBO therapy was a feasible and 
promising modality for high grade glioma, and the results 
justify further evaluation to clarify the benefits of this 
treatment regimen.  
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Purpose/Objective: The aim of the present analysis was to 
evaluate the recurrence pattern in patients with recurrent 
malignant glioma after re-irradiation with bevacizumab. 
Materials and Methods: Thirty-one patients with recurrent 
malignant glioma treated with re-irradiation and 
bevacizumab after previous chemoradiotherapy (according to 
EORTC/NCIC trial) and [18F]FET-PET and/or MRI confirmed 
recurrence were retrospectively analyzed. Bevacizumab was 
applied twice during fractionated re-irradiation (10 mg/kg, 
d1 + d15, median 36 Gy, 2 Gy single doses). Recurrence 
patterns were assessed by means of [18F]FET-PET and/or MRI. 
Results: Median follow-up was 34.0 months for all patients 
[95%-CI, 27.7-40.3] and median post-recurrence survival 10.8 
months [95%-CI, 9.2-12.4]. Concerning the recurrence 
patterns, 61.3% of these were located in-field (19 patients), 
22.6% were marginal (7 patients) and 16.1% ex-field (5 
patients). No influence on the recurrence pattern was 
observed according to sex, WHO grade, maintenance 
chemotherapy or MGMT methylation status whereas planning 
target volume (PTV) size had a significant influence on the 
recurrence pattern (p=0.032). PTV sizes > 75 ml were 
associated with a higher in-field recurrence rate and lower 
median post-recurrence progression-free survival (8.5 vs. 4.9 
months, p=0.016). 
Conclusions: After the administration of re-irradiation with 
bevacizumab the recurrence pattern seems to be mainly 
centrally located. The PTV size was the main predictor for a 
marginal/ex-field recurrence.  
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Purpose/Objective: The standard tools in the target volume 
delineation of glioblastoma multiforme (GBM) are 
gadolinium-enhanced T1-weighted (Gd-MRI) and T2-weighted 
MRI (T2-MRI); however, neither contrast enhancement nor 
edema are sufficient to accurately measure tumor extension 
in recurrent GBM. C11-methionine PET (MET-PET) is a well-
established technique for evaluating the tumor extent for the 
radiation treatment planning in brain tumor and there is a 
relationship in localization between the MET-PET uptake and 
the grade of malignancy in GBM. The purpose of this work is 
to investigate the recognition of the tumor extent and to 
define the optimal margin to Gd-MRI and T2-MRI in the re-
irradiation planning of recurrent GBM by comparison to MET-
PET. 
Materials and Methods: CT, MRI, and MET-PET were 
separately performed within 2 weeks in 25 patients with 
recurrent GBM for the re-irradiation planning. The Gd-MRI 
clinical target volume (CTV) (CTV-Gd) and the T2-MRI CTV 
(CTV-T2) were defined as the contrast-enhanced area on Gd-
MRI and the high intensity area on T2-MRI, respectively. We 
defined CTV x mm (x= 5, 10, 15, 20) as x mm outside the 
CTV. MET-PET CTV (CTV-MPET) was defined as the area of 
MET accumulation, which was higher than that of normal 
tissue on MET-PET. A threshold value of CTV-MPET for the 
tumor/normal tissue index of 1.3 was considered for 
malignant activity. We calculated the sensitivity and 
specificity of CTV-Gd and CTV-T2 by comparison to CTV-MPET 
served as the gold standard in this study. 
Results: The average CTV-MPET, CTV-Gd, and CTV-T2 volume 
were 59, 56, and 222 ml, respectively. There was no 
significant correlation between each type of the CTV in its 
size. Sensitivity of CTV-T2 5 mm (98%) was significantly 
higher than CTV-T2 (88%), and there was no significant 
difference in sensitivity between CTV-T2 5 mm and CTV-T2 
10, 15, and 20 mm. Sensitivity of CTV-Gd 20 mm (97%) was 
lower than that of CTV-T2 5 mm. The specificity of CTV-Gd 
and CTV-T2 significantly decreased in accordance with 
increases in the margin outside the CTV-Gd and CTV-T2. 
